BlackRock Inc. Takes Position in QuidelOrtho Corporation $QDEL

Key Points

• BlackRock acquired 11.2 million QuidelOrtho shares worth approximately $196.2 million, giving it a 16.43% stake. Institutional investors collectively own about 99% of the company.
• Analyst sentiment remains cautious: QuidelOrtho has an average “Reduce” rating and a $13.62 price target, below its reported opening price of $15.32.
• QuidelOrtho beat quarterly expectations with $0.13 in adjusted EPS versus a $0.05 loss estimate and revenue of $630.9 million, up 2.8% year over year; management issued full-year 2026 EPS guidance of $0.65–$0.90.

BlackRock Inc. purchased a new stake in shares of QuidelOrtho Corporation (NASDAQ:QDEL - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 11,202,523 shares of the company's stock, valued at approximately $196,212,000. BlackRock Inc. owned approximately 16.43% of QuidelOrtho as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Global Retirement Partners LLC raised its stake in shares of QuidelOrtho by 3,691.7% in the fourth quarter. Global Retirement Partners LLC now owns 910 shares of the company's stock worth $26,000 after purchasing an additional 886 shares during the last quarter. Hantz Financial Services Inc. increased its holdings in QuidelOrtho by 50.3% in the 4th quarter. Hantz Financial Services Inc. now owns 1,082 shares of the company's stock worth $31,000 after buying an additional 362 shares in the last quarter. Larson Financial Group LLC increased its holdings in QuidelOrtho by 322.2% in the 3rd quarter. Larson Financial Group LLC now owns 1,330 shares of the company's stock worth $39,000 after buying an additional 1,015 shares in the last quarter. GAMMA Investing LLC raised its position in QuidelOrtho by 67.7% in the 2nd quarter. GAMMA Investing LLC now owns 2,185 shares of the company's stock worth $38,000 after buying an additional 882 shares during the last quarter. Finally, EverSource Wealth Advisors LLC raised its position in QuidelOrtho by 250.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,230 shares of the company's stock worth $93,000 after buying an additional 2,309 shares during the last quarter. Institutional investors own 99.00% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. Weiss Ratings reiterated a "sell (e+)" rating on shares of QuidelOrtho in a research note on Friday, July 17th. UBS Group restated a "neutral" rating and set a $12.00 price objective on shares of QuidelOrtho in a research report on Thursday, May 7th. Zacks Research cut shares of QuidelOrtho from a "hold" rating to a "strong sell" rating in a report on Wednesday, August 12th. Citigroup boosted their target price on shares of QuidelOrtho from $13.00 to $18.00 and gave the company a "neutral" rating in a research note on Wednesday, July 8th. Finally, JPMorgan Chase & Co. boosted their target price on shares of QuidelOrtho from $11.00 to $12.00 and gave the company an "underweight" rating in a research note on Wednesday, July 1st. Three investment analysts have rated the stock with a Hold rating and three have given a Sell rating to the company's stock. Based on data from MarketBeat.com, QuidelOrtho currently has an average rating of "Reduce" and an average price target of $13.62.

QuidelOrtho Stock Performance

QDEL opened at $15.32 on Friday. The company's 50 day moving average is $15.91 and its 200 day moving average is $16.05. The company has a current ratio of 1.39, a quick ratio of 0.76 and a debt-to-equity ratio of 1.43. The company has a market cap of $1.05 billion, a price-to-earnings ratio of -0.99 and a beta of 0.68. QuidelOrtho Corporation has a 12-month low of $9.92 and a 12-month high of $35.58.

QuidelOrtho (NASDAQ:QDEL - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $0.13 EPS for the quarter, beating analysts' consensus estimates of ($0.05) by $0.18. The business had revenue of $630.90 million during the quarter, compared to analysts' expectations of $618.72 million. QuidelOrtho had a negative net margin of 39.20% and a positive return on equity of 4.88%. The firm's revenue was up 2.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.12 earnings per share. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. On average, equities research analysts predict that QuidelOrtho Corporation will post 0.75 EPS for the current year.

QuidelOrtho Company Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company's product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.

Want to see what other hedge funds are holding QDEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for QuidelOrtho Corporation (NASDAQ:QDEL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source